LKB1 mutations were found in about 50% of KRAS-mutated NSCLC and it was demonstrated that the co-occurrence of LKB1/KRAS mutations significantly increases the tumor burden, mediated by increased resistance to classical anticancer and immunotherapeutic drugs thus corresponding with poor prognosis for patients carrying these alterations (5, 6). Here, KRAS is linked to non-small cell lung carcinoma.